Home/ Stocks/ NEUP

Neuphoria Therapeutics Inc. Common Stock

NEUP XNAS

$2.89 +0.12 (+4.33%) ▲ 15-min delayed

Open

$2.89

High

$2.89

Low

$2.89

Volume

100

Market Cap

$15.04M

About Neuphoria Therapeutics Inc. Common Stock

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company focused on therapies for serious central nervous system disorders. Its lead product candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor. The company has discontinued development of BNC210 for social anxiety disorder, while its BNC210 program for post-traumatic stress disorder is currently paused and no active clinical trial is underway. The company operates through a single operating and reporting segment focused on the discovery and development of allosteric ion-channel modulators for serious CNS disorders with high unmet medical need.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 1 Website →

Related Market News

No specific coverage for NEUP yet. Check out our latest market news or earnings calendar.

Get NEUP Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Neuphoria Therapeutics Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.